Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

about

Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

Item

http://www.wikidata.org/entity/Q40379397

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

@en

type

Item

label

Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

@en

prefLabel

Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

@en

P1476

Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

@en

P2093

Hideki Origasa

http://www.w3.org/2001/XMLSchema#string

Satoe Shimoda

http://www.w3.org/2001/XMLSchema#string

P2860

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models.

Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Prevalence of wearing-off and dyskinesia among the patients with Parkinson's disease on levodopa therapy: a multi-center registry survey in mainland China

Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.

P2888

s00702-016-1671-x

P304

35-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00702-016-1671-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Yoshikuni Mizuno

P577

2017-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044563329

http://www.w3.org/2001/XMLSchema#string

P698

28091751

http://www.w3.org/2001/XMLSchema#string

P921

levodopa

P932

5754456

http://www.w3.org/2001/XMLSchema#string